Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy |
Gu, Yu-Lei
(Emergency Department, The First Affiliated Hospital of Zhengzhou University)
Lan, Chao (Emergency Department, The First Affiliated Hospital of Zhengzhou University) Pei, Hui (Emergency Department, The First Affiliated Hospital of Zhengzhou University) Yang, Shuang-Ning (Biological Cell Therapy Center, The First Affiliated Hospital of Zhengzhou University) Liu, Yan-Fen (Biological Cell Therapy Center, The First Affiliated Hospital of Zhengzhou University) Xiao, Li-Li (Vasculocardiology Deparment, The First Affiliated Hospital of Zhengzhou University) |
1 | Bertsch T, Aschenneller C, Bewarder N, et al (2013). European proficiency study with control serum for the tumor marker CA19-9 measured on different test system. Clin Lab, 59, 185-92. |
2 | Duraker N, Hot S, Polat Y, et al (2007). CEA, CA19-9, and CA125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol, 95, 142-7. DOI |
3 | Frucht H, Stevens PD, Fogelman DR, et al (2004). Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol, 7, 343-54. DOI |
4 | He Y, Zheng R, Li D, et al (2015). Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res, 27, 29-37. |
5 | Humphris JL, Chang DK, Johns AL, et al (2012). The prognostic and predictive value of serum CA19-9 in pancreatic cancer. Ann Oncol, 23, 1713-22. DOI |
6 | Jamieson NB, Carter CR, Mckay CJ, et al (2011). Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res, 17, 3316-31. DOI ScienceOn |
7 | Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. DOI |
8 | Jiang XT, Tao HQ, Zou SC (2004). Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int, 3, 464-8. |
9 | Li XY, Guo XZ, Li HY, et al (2014). Application of tumor markers in diagnosis and prognosis assessment of pancreatic cancinoma. Chin J Prac Int Med, 34, 499-503. |
10 | Lin QJ, Yang F, Jin C, et al (2015). Current status and progress of pancreatic cancer in China. World J Gastroenterol, 21, 7988-8003. |
11 | Liu F, Du F1, Chen X (2014). Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J Surg Oncol, 12, 333. DOI |
12 | Mu XF, Cao JX, Wang YX, et al (2011). Clinical value of serum CA19-9, CEA and CA125 in diagnosis and prognosis of unresectable pancreatic cancer patients treated with chemotherapy. Clin Focus, 26, 113-6. |
13 | Reitz D, Gerger A, Seidel J, et al (2015). Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol, 68, 427-33. DOI |
14 | Wu AZ, Liang Z, Wang HF (2011). Analysis of serum CA19-9, CA242, CA125 and CEA of pancreatic cancer patients. Chin J Lab Diagn, 15, 1087-8. |
15 | Zhou G, Niu L, Chiu D, et al (2012). Changes in the expression of serum markers CA242, CA19-9, CEA, TNF x03b1, and TSGF after eryosurgery in pancreatic cancer patients. Biotechnol Lett, 34, 1235-41. DOI ScienceOn |